BioPharmSignal logoBioPharmSignal

Biotech News

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

UroGen Pharma (URGN)UroGen PharmaEarnings

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103 Continued advancement of pipeline, with UGN-103 on track for NDA submission

Related news

URGNUroGen Pharma2026-07-29 12:00 EST

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

URGNUroGen Pharma2026-07-15 12:00 EST

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

UroGen Pharma

Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI...

Recent company news

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-07-29 12:00 EST

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

URGNUroGen Pharma2026-07-15 12:00 EST

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

URGNUroGen Pharma2026-07-08 12:00 EST

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

URGNUroGen Pharma2026-06-05 12:00 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
45.60 USD
Market cap
1.29B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States